The report expects that factors such as high efficacy, target oriented attack, higher approval success rates and a very high probability to achieve blockbuster status will continue driving this market in the foreseeable future. According to the firm’s estimates, eight out of the top ten selling drugs in 2016 will be biologicals. This is significantly higher than 2000, where only one product (Epogen/Procrit)
The report, an updated and far more analytical version of our popular 2011 study, finds that the growth of the biologicals market is creating a huge demand for efficient cold chain logistic services. The study, that has been undertaken using both desk based and qualitative primary market research, has analyzed three aspects of the global healthcare cold chain logistics market.
The first aspect involves the quantification of the global market for temperature sensitive healthcare products into three major classes and evaluation of the current and future opportunities in each of these classes. The second aspect involves an in-depth understanding on the global healthcare cold chain distribution process and logistic requirements for various temperature sensitive healthcare products. The third aspect involves the quantification of the global healthcare cold chain logistic services market and a comprehensive evaluation of its various segments.
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-
IMARC Group North America
Email: america@
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-
To know more please visit: http://www.imarcgroup.com/
